Pirfenidone (PFD) is currently one of the standard medicines authorized to treat IPF, and its therapeutic effect on IPF is related to the NRF2/BACH1 balance that regulates oxidative stress ability. The gene discussed is NFE2L2; the disease is idiopathic pulmonary fibrosis.